SBIR/STTR Research Award
Experimental Design Software for Process Development
Award amount
$388,078Program and phase
SBIR · Phase IIAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- IntelliChem Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): Reaction development, the characterization
and optimization of reactions used for synthesis, is a major bottleneck in
multi-step and compound-library synthesis for drug discovery and development
This program is aimed at developing a novel computer software application that
guides a chemist through a three-stage sequential experimentation process
consisting of: (1) reaction screening to identify the significant factors; (2)
improving the reaction and finding the region of the optimum; and (3) locating
the optimal settings. The approach integrates an eclectic combination of
technologies from experimental design, statistics, experts systems, and
laboratory automation. In Phase I, we successfully demonstrated feasibility of
the approach by constructing a prototype application and using it to solve
reaction development problems in academic and pharmaceutical research settings.
In Phase II, we will (1) extend the experimental design and analysis
capabilities of the prototype; (2) implement the capability for automated
execution of experimental designs; (3) incorporate an intelligent agent; and
(4) test, evaluate and validate the software in conjunction with academic,
pharmaceutical research, and instrument vendor collaborators. The ultimate goal
of the program is to develop a commercial software application that enables
chemists to improve their productivity and to accelerate and reduce the cost of
drug development.
PROPOSED COMMERCIAL APPLICATION:
Deployment of the software application In a drug discovery and development
organization is expected to offer 4 principal benefits: (1) improve the productivity
of the chemist; (2) increase throughput of drug candidates; (3) reduce the cost of
multi-step and compound library synthesis; and (3) shorten drug discovery and
development timelines.
Technology keywords
Not reported